How will the world's second-largest pharma market shape up in the future? What effects will policy shifts and an increasing move to generics have? Our new report explains.

Japan is the second-largest pharmaceutical market in the world. As of the 12 months to Q1 2009, the Japanese pharmaceutical market accounted for nearly 10% of the world market, and generated total sales of $71.6bn. The Japanese government ensures that all citizens and workers have health insurance. Japan's healthcare expenditures have been increasing to keep up with the aging population, but the government is increasingly concerned that the expenses are unsustainable. What will happen in the Japanese pharmaceutical market next decade? Can the market continue to rise if the government exacts even more-aggressive price cuts? Will Japan consume more generics in future years? Will the combination of Daiichi Sankyo and Ranbaxy significantly facilitate generic drug sales in Japan? Our new pharma report - Japanese Pharmaceutical Market 2009-2024 - tells you.

First, this report analyses the Japanese healthcare sector and pharmaceutical market as it currently exists. Our report includes discussions of how reimbursement levels are set, how drugs are approved, and how the healthcare insurance system works. This study analyses crucial aspects of the healthcare system that influence the prices of and demand for pharmaceuticals in Japan. This report relies upon up-to-date information from leading sources, primary in-depth research and interviews, supplemented by our original, insightful commentaries.

The majority of this new report analyses the future of the Japanese pharmaceutical market from 2009 to 2024, with our unique forward-looking analyses. This study analyses the future in qualitative and quantitative terms, in particular the factors that will change the Japanese market. What impact will the stronger yen have on pharmaceutical purchases in Japan? What impact will the recent spate of acquisitions have on the Japanese sector? This report discusses these and other factors that will change the Japanese pharma market, especially sales revenues in the overall market and leading therapeutic classes.

Comprehensive analysis of the Japanese pharma sector

Japanese Pharmaceutical Market 2009-2024 includes 76 tables and figures of recent sales data, detailed sales forecasts and supporting data. Information contained in this report includes:
• Market values for the 12 months up to the end of Q1 2009
• Sales figures for top-selling categories, including cardiovascular treatments, antiulcerants, antidepressants and antipsychotics, topical antirheumatics, systemic antihistamines, cephalosporins, antimetabolites, cancer treatments, antiviral agents and others
• Forecast sales values for the above categories from 2009-2024
• Extensive discussions for why the markets will behave as forecasted
• Forecasts for prescription drugs, branded drugs and generics
• Data showing disease prevalence and rising rates of chronic disease
• Developments toward bungyo – the separation of prescribing and dispensing functions – and its impact on the market
• Sales figures and recent market developments for leading Japanese pharmaceutical companies.

Qualitative aspects of this report cover all of the topics listed above, and also include:
• Developments regarding the doctor shortage and the impact that situation will have on Japanese healthcare in the future
• Information about other healthcare trends likely to impact upon pharmaceutical sales in Japan
• Discussions of the effects of the changing value of the yen
• Discussions of mergers and acquisitions in Japanese pharma.

Crucial questions answered by Japanese Pharmaceutical Market 2009-2024

Japanese Pharmaceutical Market 2009-2024 provides hard data about the Japanese pharmaceutical sector. In particular, our new study answers crucial questions such as:
• What are the current highest-selling drugs in Japan, by product and class?
• How will their sales develop by 2014, 2019 and 2024?
• Which drug categories will experience the fastest growth over the next 15 years? Why?
• Which drug categories will lose market share over the next 15 years? Why?
• What impact will bungyo have on the sales of antibiotics?
• Why do the Japanese tend not to consume generics in large quantities?
• What will be the impact of the governmental push towards generics?
• What is the doctor shortage like, and why does it exist?
• What changes are taking place in the pharmacist-education sector?
• What are the most-common types of cancers in Japan?
• What major Japanese pharmaceutical companies posted sales increases last year or last quarter?
• Which Japanese companies are buying companies in the US and elsewhere?

Main benefits that you will receive from reading Japanese Pharmaceutical Market 2009-2024

This report will give you the qualitative and quantitative information that you need to assess the Japanese pharmaceutical market. Consequently, you will be able to understand its likely future behaviour and sales potential, taking into account regulatory, social and developmental complexities. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion to benefit your work.

You can obtain this report today

Japanese Pharmaceutical Market 2009-2024 will provide your organisation with the information it needs to understand this large, changing pharma market - one with great international significance. Japan has many significant opportunities for domestic and foreign companies, in both original-branded and generic pharmaceuticals. You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6